Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

FULVICIN U/F TAB 250MG 250 MG

GRISEOFULVIN : 250 MG · DIN 00028274 · SCHERING-PLOUGH CANADA INC

Health Canada status: CANCELLED POST MARKET

What is FULVICIN U/F TAB 250MG?

FULVICIN U/F TAB 250MG 250 MG contains GRISEOFULVIN : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00028274, held by SCHERING-PLOUGH CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Jul-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

Product details and regulatory record

DIN00028274
Brand nameFULVICIN U/F TAB 250MG
Generic / active ingredientGRISEOFULVIN : 250 MG
ManufacturerSCHERING-PLOUGH CANADA INC
Strength250 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeD01BA01 GRISEOFULVIN
AHFS class08:14.92
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date21-Jul-2004
Original market date1966-12-31 00:00:00

What can be used instead?

Other Canadian products sharing ATC code D01BA01 GRISEOFULVIN. 0 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
FULVICIN PG TAB 330MG330 MGTABLETSCHERING-PLOUGH CANADA INCCANCELLED POST MARKETDIN 00513237
FULVICIN UF TAB 500MG500 MGTABLETSCHERING-PLOUGH CANADA INCCANCELLED POST MARKETDIN 00028282
GRISOVIN FP TAB 125MG125 MGTABLETGLAXO CANADA INCCANCELLED POST MARKETDIN 00012246
GRISOVIN FP TAB 250MG250 MGTABLETGLAXO CANADA INCCANCELLED POST MARKETDIN 00012254
GRISOVIN FP TAB 500MG500 MGTABLETGLAXO CANADA INCCANCELLED POST MARKETDIN 00012262
GRISOVIN-FP 125MG TAB125 MGTABLETROBERTS PHARMACEUTICAL CANADA INC.CANCELLED POST MARKETDIN 02100266
GRISOVIN-FP 250MG TAB250 MGTABLETROBERTS PHARMACEUTICAL CANADA INC.CANCELLED POST MARKETDIN 02100274

Who else supplies GRISEOFULVIN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. GRISEOFULVIN appears in 13 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 00028274. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.